Dod Biotech Public Stock Fundamentals
| DOD Stock | 2.18 0.04 1.87% |
DOD Biotech Public fundamentals help investors to digest information that contributes to DOD Biotech's financial success or failures. It also enables traders to predict the movement of DOD Stock. The fundamental analysis module provides a way to measure DOD Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DOD Biotech stock.
DOD |
DOD Biotech Public Company Operating Margin Analysis
DOD Biotech's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current DOD Biotech Operating Margin | 0.10 % |
Most of DOD Biotech's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DOD Biotech Public is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, DOD Biotech Public has an Operating Margin of 0.1044%. This is 100.32% lower than that of the Consumer Defensive sector and 98.85% lower than that of the Packaged Foods industry. The operating margin for all Thailand stocks is 101.89% lower than that of the firm.
DOD Biotech Public Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining DOD Biotech's current stock value. Our valuation model uses many indicators to compare DOD Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across DOD Biotech competition to find correlations between indicators driving DOD Biotech's intrinsic value. More Info.DOD Biotech Public is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.70 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for DOD Biotech Public is roughly 1.42 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DOD Biotech's earnings, one of the primary drivers of an investment's value.DOD Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DOD Biotech's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DOD Biotech could also be used in its relative valuation, which is a method of valuing DOD Biotech by comparing valuation metrics of similar companies.DOD Biotech is currently under evaluation in operating margin category among its peers.
DOD Fundamentals
| Return On Equity | 0.04 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.10 % | |||
| Current Valuation | 2.04 B | |||
| Shares Outstanding | 410 M | |||
| Shares Owned By Insiders | 48.01 % | |||
| Shares Owned By Institutions | 2.38 % | |||
| Price To Book | 1.47 X | |||
| Price To Sales | 2.55 X | |||
| Revenue | 1.02 B | |||
| Gross Profit | 437.65 M | |||
| EBITDA | 338.82 M | |||
| Net Income | 49.79 M | |||
| Total Debt | 19.31 M | |||
| Book Value Per Share | 3.03 X | |||
| Cash Flow From Operations | 145 M | |||
| Earnings Per Share | 0.12 X | |||
| Target Price | 14.0 | |||
| Beta | 1.3 | |||
| Market Capitalization | 2.17 B | |||
| Total Asset | 1.63 B | |||
| Z Score | 67.2 | |||
| Net Asset | 1.63 B |
About DOD Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DOD Biotech Public's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DOD Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DOD Biotech Public based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in DOD Stock
DOD Biotech financial ratios help investors to determine whether DOD Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DOD with respect to the benefits of owning DOD Biotech security.